RecruitMe Clinical Trial

Eradicating Barrett's Esophagus Using Radiofrequency Ablation or a Novel Hybrid Argon PlasmaCoagulation Technique
Eradicating Barrett's Esophagus Using Radiofrequency Ablation or a Novel Hybrid Argon Plasma Coagulation Technique (BURN)
Sponsor:Erbe USA, Incorporated
Enrolling:Male and Female Patients
Age Range:Between 18 and 85 years old
IRB Number:AAAR9167
U.S. Government ID:NCT03621319
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

The purpose of the study is to compare two types of endoscopic treatments in patients with Barretts esophagus (BE) with abnormal cells (dysplasia); radiofrequency ablation (RFA) and hybrid argon plasma coagulation (H-APC). H-APC is a newer technique in the treatment of BE and has not been adequately studied and is not approved by the FDA for routine use. This study is being conducted to better understand how H-APC works in the treatment of BE and compare it to RFA treatment.

Do You Qualify?
Are Are you between 18-85 years of age?YesNo
Do you have a confirmed diagnosis of Barrett's Esophagus with abnormal cells (dysplastic)?YesNo
Have you not received any prior ablative endoscopic treatment?YesNo
Submit
Cancel
Investigator
Julian Abrams, MD, MPH
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162